Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 29, 2026 16:05 ET | Source: Abivax

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database

Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance...
June 29, 2026 16:05 ET | Source: Abivax

Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant un bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité

Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant un bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité ...
June 29, 2026 16:05 ET | Source: Nasdaq, Inc.

Nasdaq to Hold Second Quarter 2026 Investor Conference Call

NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) has scheduled its second quarter 2026 financial results announcement. Who:Nasdaq’s CEO, CFO, and additional members of its senior...
June 29, 2026 16:05 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease

IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy...
June 29, 2026 16:01 ET | Source: Bank OZK

Bank OZK Announces $200 Million Stock Repurchase Program

LITTLE ROCK, Ark., June 29, 2026 (GLOBE NEWSWIRE) -- Bank OZK (the “Bank”) (Nasdaq: OZK) today announced that its Board of Directors has approved a stock repurchase program (the “Stock Repurchase...
June 29, 2026 16:01 ET | Source: Nuvectis Pharma, Inc.

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

FORT LEE, NJ, June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment...
June 29, 2026 16:01 ET | Source: Concentrix Solutions Corporation

Concentrix Reports Second Quarter 2026 Results

Concentrix Corporation (NASDAQ: CNXC) today announced financial results for its fiscal second quarter ended May 31, 2026.
June 29, 2026 16:00 ET | Source: DBV Technologies S.A.

DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing

Châtillon, France, June 29, 2026 DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review...
June 29, 2026 16:00 ET | Source: DBV Technologies S.A.

DBV Technologies fait le point sur le dépôt du dossier BLA pour le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans; la Société travaille en collaboration avec la FDA afin d'optimiser le processus d'examen en vue du dépôt du dossier

Châtillon, France, le 29 juin (22 :00 CEST) 2026 DBV Technologies fait le point sur le dépôt du dossier BLA pour le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans ; la Société travaille en...
June 29, 2026 15:30 ET | Source: Creative Global Technology Holdings Limited

Creative Global Technology Holdings Limited Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

HONG KONG, June 29, 2026 (GLOBE NEWSWIRE) -- Creative Global Technology Holdings Limited (“CGTL”, the “Company”, or “we”) (NASDAQ: CGTL), a Hong Kong-based company sourcing and reselling recycled...